Kura Oncology (NASDAQ:KURA) Reaches New 12-Month Low – Here’s Why

Kura Oncology, Inc. (NASDAQ:KURA)’s stock price reached a new 52-week low during trading on Thursday . The company traded as low as $9.63 and last traded at $9.72, with a volume of 742124 shares trading hands. The stock had previously closed at $10.20.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on KURA shares. UBS Group initiated coverage on Kura Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. Wedbush reissued an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. Stifel Nicolaus cut shares of Kura Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.38.

Kura Oncology Trading Down 0.6 %

The stock has a market capitalization of $748.83 million, a PE ratio of -4.08 and a beta of 0.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company’s 50 day moving average price is $15.17 and its two-hundred day moving average price is $18.56.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently made changes to their positions in KURA. Suvretta Capital Management LLC boosted its holdings in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after purchasing an additional 583,155 shares during the last quarter. Armistice Capital LLC lifted its holdings in Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares during the last quarter. Geode Capital Management LLC grew its position in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after acquiring an additional 41,535 shares during the period. Franklin Resources Inc. increased its stake in Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after acquiring an additional 23,113 shares during the last quarter. Finally, Candriam S.C.A. raised its position in Kura Oncology by 39.2% in the second quarter. Candriam S.C.A. now owns 906,482 shares of the company’s stock valued at $18,664,000 after purchasing an additional 255,065 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.